DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Dated: May 2, 2012.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–11074 Filed 5–7–12; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Grand Opportunity in Medications Development for Substance-Related Disorders (U01).

Opportunity in Medications Development for Drug Abuse Special Emphasis Panel; Grand Incentive of Personal Privacy.

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Date: May 23, 2012.

Time: 8:00 a.m. to 5:00 p.m.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Grand Opportunity in Medications Development for Substance-Related Disorders (U01).

Date: June 6, 2012.

Time: 9:00 a.m. to 5:00 p.m.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Regulatory Affairs Support (8902).

Date: May 30, 2012.

Time: 9:30 a.m. to 1:30 p.m.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Regulatory Affairs Support (8902).

Date: June 6, 2012.

Time: 8:00 a.m. to 2:00 p.m.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: June 6, 2012.

Time: 8:00 a.m. to 2:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: June 6, 2012.

Time: 8:00 a.m. to 2:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: June 6, 2012.

Time: 8:00 a.m. to 2:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: June 6, 2012.

Time: 8:00 a.m. to 2:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: June 6, 2012.

Time: 8:00 a.m. to 2:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: May 23, 2012.

Time: 8:00 a.m. to 5:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: May 23, 2012.

Time: 8:00 a.m. to 5:00 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: May 30, 2012.

Time: 9:30 a.m. to 1:30 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: May 30, 2012.

Time: 9:30 a.m. to 1:30 p.m.

Name of Committee: National Institute of Nursing Research Special Emphasis Panel; HIV Palliative Care RFA Review.

Date: May 23, 2012.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review Officer, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Blvd., Room 4238, MSC 9550, Bethesda, MD 20892–9550, 301–402–6626, gm145a@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHSS)

Dated: May 2, 2012.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–11077 Filed 5–7–12; 8:45 am]
BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse

Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 USC, as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Regulatory Affairs Support (8902).

Date: June 6, 2012.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Lyle Furr, Contract Review Specialist, Office of Extramural Affairs, National Institute on Drug Abuse, NIH, DHHS, Room 4227, MSC 9550, 6001 Executive Boulevard, Bethesda, MD 20892–9550, (301) 435–1439, If33c@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHSS)

Dated: May 2, 2012.

Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2012–11075 Filed 5–7–12; 8:45 am]
BILLING CODE 4140–01–P